FDA
-
-
-
-
-
-
-
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Rezolute (rzlt)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)
-
-
-
-
-
-
-
Rezolute Inc. (RZLT): FDA Grants Orphan Drug Designation to Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
-
-
-
-
-
-
-
Rezolute (RZLT) PT Raised to $15 at BTIG
-
-
-
-
-
-
-
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

